Cost-Effectiveness of Recently Approved Gene and Cell Therapies for Ultra-Rare Pediatric Disorders: Implications for Genomic Medicine and Expanded Newborn Screening
Genetics in Medicine Open · 2026-11 · 104523
DOI: 10.1016/j.gimo.2026.104523 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics in Medicine Open, 2026-11. Verfasst von Laura N. Venditti und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Human Genome Research Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- National Human Genome Research Institute
Zitieren
APA
Venditti, L. N., Lavelle, T. A., & Venditti, C. P. (2026). Cost-Effectiveness of Recently Approved Gene and Cell Therapies for Ultra-Rare Pediatric Disorders: Implications for Genomic Medicine and Expanded Newborn Screening. Genetics in Medicine Open, 104523. https://doi.org/10.1016/j.gimo.2026.104523
Vancouver
Venditti LN, Lavelle TA, Venditti CP. Cost-Effectiveness of Recently Approved Gene and Cell Therapies for Ultra-Rare Pediatric Disorders: Implications for Genomic Medicine and Expanded Newborn Screening. Genetics in Medicine Open. 2026:104523. doi:10.1016/j.gimo.2026.104523
BibTeX
@article{Venditti2026,
author = {Venditti, Laura N. and Lavelle, Tara A. and Venditti, Charles P.},
title = {Cost-Effectiveness of Recently Approved Gene and Cell Therapies for Ultra-Rare Pediatric Disorders: Implications for Genomic Medicine and Expanded Newborn Screening},
journal = {Genetics in Medicine Open},
year = {2026},
pages = {104523},
doi = {10.1016/j.gimo.2026.104523}
}
EUVIMED